{
  "id": "589a247078275d0c4a000035",
  "type": "factoid",
  "question": "Dinutuximab is used for treatment of which disease?",
  "ideal_answer": "Dinutuximab, a monoclonal antibody against disialoganglioside, is used for treatment of high-risk neuroblastoma.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/26934530",
    "http://www.ncbi.nlm.nih.gov/pubmed/26917818",
    "http://www.ncbi.nlm.nih.gov/pubmed/27756784",
    "http://www.ncbi.nlm.nih.gov/pubmed/26791869",
    "http://www.ncbi.nlm.nih.gov/pubmed/28748630",
    "http://www.ncbi.nlm.nih.gov/pubmed/28061552",
    "http://www.ncbi.nlm.nih.gov/pubmed/25940913",
    "http://www.ncbi.nlm.nih.gov/pubmed/26891967",
    "http://www.ncbi.nlm.nih.gov/pubmed/28389455"
  ],
  "snippets": [
    {
      "text": "PURPOSE: Dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26791869",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dinutuximab: A Review in High-Risk Neuroblastoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26891967",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Dinutuximab (ch14.18; Unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. This intravenous drug is approved in the EU and USA as combination therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26891967",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dinutuximab administered in combination with GM-CSF, IL-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26891967",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26934530",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The combination of cytokines IL-2 and GM-CSF with the anti-GD2 MoAb ch14.18 (Dinutuximab) has shown a significant improvement in outcome for HR-NB. The FDA and EMA approved dinutuximab (Unituxin(R)) in 2015 for the treatment of patients with HR-NB who achieved at least a partial response after multimodality therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26934530",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Severe adverse effects of dinutuximab include pain, hypersensitivity reactions, capillary leak syndrome, and hypotension.<br><b>CONCLUSIONS</b>: Dinutuximab is the first anti-GD2 monoclonal antibody approved in combination with GM-CSF, IL-2, and RA for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26917818",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dinutuximab is a chimeric, human-murine, anti-GD2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin (interleukin-2 [IL-2]), and isotretinoin (13-cis-retinoic acid [RA]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26917818",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The recommended dosage of dinutuximab is 17.5 mg/m<br><b>CONCLUSION</b>: Dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.<br>",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28389455",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Immunotherapy with the anti-GD2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28748630",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "<b>PURPOSE</b>: The pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.<br><b>SUMMARY</b>: Dinutuximab (Unituxin, United Therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28389455",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This article summarizes the milestones in the development of dinutuximab leading to this first approval for use (in combination with granulocyte macrophage colony-stimulating factor, interleukin-2 and 13-cis retinoic acid) in the treatment of paediatric patients with high-risk neuroblastoma who achieve at least partial response to prior first-line multiagent, multimodality therapy.<br>",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25940913",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The US FDA has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25940913",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "United Therapeutics Corporation and the National Cancer Institute are developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25940913",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "TGF\u03b2R1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27756784",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "PURPOSE: Immunotherapy of high-risk neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (ADCC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27756784",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dinutuximab is a chimeric, human-murine, anti-GD2 monoclonal antibody approved in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin (interleukin-2 [IL-2]), and isotretinoin (13-cis-retinoic acid [RA]) for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26917818",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS Dinutuximab is the first anti-GD2 monoclonal antibody approved in combination with GM-CSF, IL-2, and RA for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26917818",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "United Therapeutics Corporation and the National Cancer Institute are developing dinutuximab (Unituxin\u2122; ch14.18), a monoclonal antibody targeting GD2, for the treatment of neuroblastoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25940913",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SUMMARY Dinutuximab (Unituxin, United Therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28389455",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION Dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28389455",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dinutuximab (formerly called ch14.18), a monoclonal antibody targeting the disialoganglioside GD2, has been shown to significantly improve survival rates in patients with high-risk neuroblastoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28061552",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dinutuximab (ch14.18; Unituxin\u2122) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26891967",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The US FDA has recently approved the use of dinutuximab combination therapy for the treatment of high-risk neuroblastoma in paediatric patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25940913",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26934530",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: A case series.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28748630",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Findings of the randomized phase III study (ANBL0032) led to the approval of dinutuximab for the treatment of children with high-risk neuroblastoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28061552",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "https://meshb.nlm.nih.gov/record/ui?ui=D013812",
    "https://meshb.nlm.nih.gov/record/ui?ui=D004194"
  ],
  "exact_answer": "neuroblastoma"
}